Zoster Reactivation Risk in Patients Treated with Cyclophosphamide

Susan Bernstein is a freelance medical journalist based in Atlanta.

References

1. Garnier C, Ribes D, Chauveau D, et al. Zoster after cyclophosphamide for systemic lupus erythematosus or vasculitis: Incidence, risk factors, and effect of antiviral prophylaxis. J Rheumatol. 2018 Jul;180310. Epub ahead of print.
2. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008 Feb;67(2):195–205.
3. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583–1594.
4. Hoffman GS, Leavitt RY, Fauci AS, et al. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum. 1989 Dec;32(12):1626–1627.
5. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014 Apr;42(2):325–334.
6. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488–498.
7. Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis. 2009 May;68(5):658–663.
8. Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005 Dec;118(12):1416.
9. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103–108.